Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.","authors":"Rachael Straining, Francine Foss, Molly Schiffer, Kejal Amin, Sonal Agarwal, Iris Isufi, Scott Huntington, Shalin Kothari, Stuart Seropian, Michael Girardi, Tarsheen Sethi","doi":"10.1016/j.clml.2024.09.005","DOIUrl":"https://doi.org/10.1016/j.clml.2024.09.005","url":null,"abstract":"<p><strong>Background: </strong>T-cell lymphomas are a heterogeneous group of lymphoid malignancies with poor outcomes. Frontline multiagent chemotherapy options include CHOP (prednisone, vincristine, cyclophosphamide, and doxorubicin), brentuximab-CHP, CHOEP, and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin).</p><p><strong>Patients and methods: </strong>We report our single institution data for safety and efficacy of EPOCH in 38 patients with aggressive T-cell lymphoma including both peripheral T cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).</p><p><strong>Results: </strong>Eighteen patients received EPOCH as first-line and 21 in the relapsed/refractory (R/R) setting. In 36 evaluable patients, the overall response rate (ORR) was 77% (95% CI, 61%-89%) with 19 (53%) patients achieving complete response (CR) (95% CI, 36%-69%). The ORR in first line and R/R settings were 80% (95% CI, 46%-94%) and 75% (95% CI, 52%-90%), respectively. Response rate was similar in African American versus Caucasian patients but was higher in CD30 negative versus positive patients. Most common grade 3/4 adverse events included cytopenias.</p><p><strong>Conclusions: </strong>Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.","authors":"Massimo Breccia, Rosalba Cucci, Giovanni Marsili, Fausto Castagnetti, Sara Galimberti, Barbara Izzo, Federica Sorà, Simona Soverini, Monica Messina, Alfonso Piciocchi, Massimiliano Bonifacio, Daniela Cilloni, Alessandra Iurlo, Giovanni Martinelli, Gianantonio Rosti, Fabio Stagno, Paola Fazi, Marco Vignetti, Fabrizio Pane","doi":"10.1016/j.clml.2024.08.009","DOIUrl":"https://doi.org/10.1016/j.clml.2024.08.009","url":null,"abstract":"<p><strong>Background: </strong>In the last decade, TKIs improved the overall survival (OS) of chronic myeloid leukemia (CML) patients who achieved a deep and sustained molecular response (DMR, defined as stable MR4 and MR4.5). Those patients may attempt therapy discontinuation. In our analysis, we report the differences in eligibility criteria due to time of response and different TKI used as frontline treatment analyzed in a large cohort of CP-CML patients.</p><p><strong>Methods: </strong>Data were exported by LabNet CML, a network founded by GIMEMA in 2014. The network standardized and harmonized the molecular methodology among 51 laboratories distributed all over Italy for the diagnosis and molecular residual disease (MRD) monitoring.</p><p><strong>Results: </strong>Out of 1777 patients analyzed, 774 had all evaluable timepoints (3, 6, and 12 months). At 3 months, 40 patients obtained ≥MR4: of them 14 (3.6%) with imatinib, 8 (5.8%) with dasatinib, and 18 (7.4%) with nilotinib (P = .093); at 6 months, 146 patients were in MR4: 42 (11%) with imatinib, 38 (28%) with dasatinib, and 66 (27%) with nilotinib (P < .001). At 12 months, 231 patients achieved a DMR: 85 (22%) with imatinib, 55 (40%) with dasatinib and 91 (38%) with nilotinib (P < .001). Achieving at least ≥MR2 at 3 months, was predictive of a DMR at any timepoint of observation: with imatinib 67% versus 30% of patients with <MR2, with dasatinib 66% versus 28% of patients with <MR2, and with nilotinib 75% versus 30% of patients with < MR2 (P < .001). At the same time point, achieving at least ≥MR3 is even more predictive of a DMR at any timepoint: 89% versus 38% of patients with <MR3 with imatinib (P < .001), 84% versus 40% of patients with <MR3 with dasatinib (P < .001), and 89% versus 49% of patients with <MR3 with nilotinib (P < .001). Of 908 patients who reached a DMR, 461 (51%) lost it: the loss of response after >2 years was significant for patients who at 3 months had ≥MR2 (18% vs. 9.9% of pts with <MR2, P = .038).</p><p><strong>Conclusion: </strong>In conclusion, reaching ≥MR2 and a MR3 at 3 months it seems predictive of a DMR at any time point. Considering the prerequisite for a discontinuation with a sustained DMR only a minority of patients can be eligible for the discontinuation, regardless the frontline treatment received.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease.","authors":"Michael Schneider, Sunita D Nasta, Stefan K Barta, Elise A Chong, Jakub Svoboda, Stephen J Schuster, Daniel J Landsburg","doi":"10.1016/j.clml.2024.08.010","DOIUrl":"https://doi.org/10.1016/j.clml.2024.08.010","url":null,"abstract":"<p><strong>Background: </strong>Large B cell lymphoma (LBCL) is the most common form of lymphoma. Polatuzumab vedotin (polatuzumab) is an effective therapy for patients diagnosed with LBCL; however, only limited information regarding pathologic features detected by clinical laboratory assays is available to determine which patients are most likely to benefit from polatuzumab based therapies.</p><p><strong>Patients and methods: </strong>We collected data from real world patients with relapsed or refractory LBCL whose tumors underwent next generation sequencing and were treated with polatuzumab based therapy at a single large academic cancer center. Tumor and patient characteristics were analyzed to look for factors that predict response to polatuzumab based therapies.</p><p><strong>Results: </strong>We identified high grade B cell lymphoma (HGBL) -NOS or MYC/BCL2 histology and presence of MYC rearrangement as factors that predict inferior response to polatuzumab based therapy. Patients with germinal center B cell of origin (GCB COO) LBCL without these factors had a high response rate (73%) to polatuzumab based therapy.</p><p><strong>Conclusion: </strong>In a single center real world retrospective analysis of R/R LBCL patients with available genomic data, polatuzumab based therapy may be less effective in patients with HGBL-NOS or MYC/BCL2 histology and MYC rearrangements, but not in patients with GCB COO LBCL without these features. Routine performance of more comprehensive pathologic analysis of tumors may inform the use of polatuzumab based therapy in patients with LBCL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma","authors":"Bruno Costa,&nbsp;Carlyn Tan,&nbsp;Tala Shekarkhand,&nbsp;Ross Firestone,&nbsp;Eric Jurgens,&nbsp;Kevin Miller,&nbsp;Alexander Lesokhin,&nbsp;Gunjan Shah,&nbsp;Neha Korde,&nbsp;Sridevi Rajeeve,&nbsp;David Chung,&nbsp;Heather Landau,&nbsp;Michael Scordo,&nbsp;Hani Hassoun,&nbsp;Kylee Maclachlan,&nbsp;Urvi Shah,&nbsp;Malin Hultcrantz,&nbsp;Issam Hamadeh,&nbsp;Sergio Giralt,&nbsp;Sham Mailankody,&nbsp;Hamza Hashmi","doi":"10.1016/S2152-2650(24)01915-3","DOIUrl":"10.1016/S2152-2650(24)01915-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S46-S47"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma","authors":"Christopher Parrish,&nbsp;Alexandra Welsh,&nbsp;John Ashcroft,&nbsp;Catherine Olivier,&nbsp;Anna Hockaday,&nbsp;Jamie Cavenagh,&nbsp;John Snowden,&nbsp;Mark Drayson,&nbsp;Ruth De Tute,&nbsp;Roger Owen,&nbsp;Kwee Yong,&nbsp;Mamta Garg,&nbsp;Kevin Boyd,&nbsp;Hamdi Sati,&nbsp;Sharon Gillson,&nbsp;Jeanine Richards,&nbsp;Mark Cook,&nbsp;Lesley Roberts,&nbsp;David Cairns,&nbsp;Gordon Cook","doi":"10.1016/S2152-2650(24)01900-1","DOIUrl":"10.1016/S2152-2650(24)01900-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S37-S38"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)","authors":"Andrew Spencer,&nbsp;Marc-Steffen Raab,&nbsp;Shinsuke Iida,&nbsp;María-Victoria Mateos Manteca,&nbsp;Michele Cavo,&nbsp;Paula Rodriguez-Otero,&nbsp;P. Joy Ho,&nbsp;Yunxin Chen,&nbsp;Paul Ferguson,&nbsp;Irit Avivi,&nbsp;Paolo Corradini,&nbsp;Esther Chan,&nbsp;Andy Chen,&nbsp;Bertrand Arnulf,&nbsp;Udo Holtick,&nbsp;Adam Sperling,&nbsp;Jufen Chu,&nbsp;David Pearson,&nbsp;Davide Germano,&nbsp;Ronan Feighery,&nbsp;Nikhil Munshi","doi":"10.1016/S2152-2650(24)01853-6","DOIUrl":"10.1016/S2152-2650(24)01853-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S8-S9"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8","authors":"Meletios Dimopoulos,&nbsp;Meral Beksac,&nbsp;Ludek Pour,&nbsp;Sosana Delimpasi,&nbsp;Vladimir Vorobyev,&nbsp;Hang Quach,&nbsp;Ivan Spicka,&nbsp;Jakub Radocha,&nbsp;Pawel Robak,&nbsp;Kihyun Kim,&nbsp;Michele Cavo,&nbsp;Kazuhito Suzuki,&nbsp;Jodie Wilkes,&nbsp;Kristin Morris,&nbsp;Farrah Pompilus,&nbsp;Molly Purser,&nbsp;Amy Philips-Jones,&nbsp;Xiaoou Zhou,&nbsp;Giulia Fulci,&nbsp;Neal Sule,&nbsp;Suzanne Trudel","doi":"10.1016/S2152-2650(24)01854-8","DOIUrl":"10.1016/S2152-2650(24)01854-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Page S9"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-015 Response of CD8+ T Lymphocytes Under Stimulation of Dendritic Cells Fused With Multiple Myeloma Plasma Cells","authors":"Thamiris De Lima,&nbsp;Maria Eduarda Barbosa,&nbsp;Ana Sheila Campos,&nbsp;Carmen Nogueira,&nbsp;Helio Dutra,&nbsp;Angelo Maiolino","doi":"10.1016/S2152-2650(24)01918-9","DOIUrl":"10.1016/S2152-2650(24)01918-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S48-S49"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-56 Single Cell Analyses of Bone Marrow Immune Microenvironment in RRMM Subjects Treated with MEK1/2 Inhibitors Reveal IRF1-Mediated IFN/PDL1 Signaling Axes","authors":"Chaitanya Acharya,&nbsp;Reyka Jayasinghe,&nbsp;Mark Hamilton,&nbsp;Sacha Gnjatic,&nbsp;Seunghee Kim-Schulze,&nbsp;Hearn Cho,&nbsp;Shaji Kumar,&nbsp;George Mulligan","doi":"10.1016/S2152-2650(24)01897-4","DOIUrl":"10.1016/S2152-2650(24)01897-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Pages S35-S36"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA","authors":"David Fandrei,&nbsp;Michael Rade,&nbsp;Markus Kreuz,&nbsp;Luise Fischer,&nbsp;Patrick Born,&nbsp;Sabine Seiffert,&nbsp;Andreas Boldt,&nbsp;Jonathan Scolnick,&nbsp;Lakshmi Venkatraman,&nbsp;Stacy Xu,&nbsp;Ronny Baber,&nbsp;Song Yau Wang,&nbsp;Enrica Bach,&nbsp;Sandra Hoffmann,&nbsp;Klaus H. Metzeler,&nbsp;Marco Herling,&nbsp;Madlen Jentzsch,&nbsp;Carmen Herling,&nbsp;Georg-Nikolaus Franke,&nbsp;Ulrike Köhl,&nbsp;Maximilan Merz","doi":"10.1016/S2152-2650(24)01922-0","DOIUrl":"10.1016/S2152-2650(24)01922-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Page S51"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}